Bristol Myers claims Phase 2 success for GPRC5D-directed CAR-T

CAR-T therapy has revolutionized blood cancer treatment, particularly in multiple myeloma. But an ongoing concern remains: If patients’ cancers progress after receiving CAR-T, what other options do they have? A Phase 2 study at Bristol ...